Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL platform

BMC Medical Genomics

Volumn 3, Issue , 2010, Pages

  Reinholz, Monica M ^a   Eckel Passow, Jeanette E ^a   Anderson, S Keith ^a   Asmann, Yan W ^a   Zschunke, Michael A ^a   Oberg, Ann L ^a   McCullough, Ann E ^b   Dueck, Amylou C ^c   Chen, Beiyun ^a   April, Craig S ^d   Wickham Garcia, Eliza ^d   Jenkins, Robert B ^a   Cunningham, Julie M ^a   Jen, Jin ^a   Perez, Edith A ^e   Fan, Jian Bing ^d   Lingle, Wilma L ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c Section of Biostatistics   (United States)

^d ILLUMINA INC   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACULOVIRAL IAP REPEAT CONTAINING PROTEIN 5; CARRIER PROTEIN; CELL CYCLE PROTEIN 2 PROTEIN; CYCLIN A2; DNA TOPOISOMERASE (ATP HYDROLYSING) A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; FORMALDEHYDE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; ONCOPROTEIN; PARAFFIN; PROTEIN P53; PROTEIN V FOS; UNCLASSIFIED DRUG; WNT5A PROTEIN; HER2 PROTEIN, HUMAN;

ADULT; ARTICLE; BASE PAIRING; BREAST TUMOR; CONTROLLED STUDY; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE REGULATORY NETWORK; GENE REPLICATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; ONCOGENE; PRIORITY JOURNAL; RNA ANALYSIS; SEQUENCE ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MITOCHONDRION; PATHOLOGY;

AVES; MURINAE;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOCHONDRIA; PARAFFIN EMBEDDING; RECEPTOR, ERBB-2;

EID: 78650259103     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-3-60     Document Type: Article

References (48)

1. The role of molecular analysis in breast cancer. FC Geyer C Marchio JS Reis-Filho, Pathology 2009 41 1 77 88 10.1080/00313020802563536 19089743
2. High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic? AH Sims KR Ong RB Clarke A Howell, Breast Cancer Res 2006 8 5 214 10.1186/bcr1605 17076877
3. Molecular Profiling in Breast Cancer. E Perez A Enui, Breast Cancer and Molecular Medicine Berlin: Springer, Piccart MJ, Wood WC, Hung C-M, Solin LJ, Cardoso F, 2006 977 1006 full-text
4. Molecular portraits of human breast tumours. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov C Williams SX Zhu PE Lonning AL Borresen-Dale PO Brown D Botstein, Nature 2000 406 6797 747 752 10.1038/35021093 10963602
5. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn SS Jeffrey T Thorsen H Quist JC Matese PO Brown D Botstein P Eystein Lonning AL Borresen-Dale, Proc Natl Acad Sci USA 2001 98 19 10869 10874 10.1073/pnas.191367098 11553815
6. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. XJ Ma Z Wang PD Ryan SJ Isakoff A Barmettler A Fuller B Muir G Mohapatra R Salunga JT Tuggle Y Tran D Tran A Tassin P Amon W Wang W Wang E Enright K Stecker E Estepa-Sabal B Smith J Younger U Balis J Michaelson A Bhan K Habin TM Baer J Brugge DA Haber MG Erlander DC Sgroi, Cancer Cell 2004 5 6 607 616 10.1016/j.ccr.2004.05.015 15193263
7. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. S Paik S Shak G Tang C Kim J Baker M Cronin FL Baehner MG Walker D Watson T Park W Hiller ER Fisher DL Wickerham J Bryant N Wolmark, N Engl J Med 2004 351 27 2817 2826 10.1056/NEJMoa041588 15591335
8. A gene-expression signature as a predictor of survival in breast cancer. MJ van de Vijver YD He LJ van't Veer H Dai AA Hart DW Voskuil GJ Schreiber JL Peterse C Roberts MJ Marton M Parrish D Atsma A Witteveen A Glas L Delahaye T van der Velde H Bartelink S Rodenhuis ET Rutgers SH Friend R Bernards, N Engl J Med 2002 347 25 1999 2009 10.1056/NEJMoa021967 12490681 (Pubitemid 35461656)
9. Gene expression profiling predicts clinical outcome of breast cancer. LJ van 't Veer H Dai MJ van de Vijver YD He AA Hart M Mao HL Peterse K van der Kooy MJ Marton AT Witteveen GJ Schreiber RM Kerkhoven C Roberts PS Linsley R Bernards SH Friend, Nature 2002 415 6871 530 536 11823860
10. Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. M Bibikova D Talantov E Chudin JM Yeakley J Chen D Doucet E Wickham D Atkins D Barker M Chee Y Wang JB Fan, Am J Pathol 2004 165 5 1799 1807 15509548
11. Quantitative Expression Profiling of RNA from Formalin-Fixed, Paraffin-Embedded Tissues Using Randomly Assembled Bead Arrays. M Bibikova J Yeakley J Wang-Rodriguez J Fan, Methods in Molecular Biology 2007 349 (Chapter 11) 159 176
12. Gene expression profiles in formalin-fixed, paraffin-embedded tissues obtained with a novel assay for microarray analysis. M Bibikova JM Yeakley E Chudin J Chen E Wickham J Wang-Rodriguez JB Fan, Clin Chem 2004 50 12 2384 2386 10.1373/clinchem.2004.037432 15563488
13. A versatile assay for high-throughput gene expression profiling on universal array matrices. JB Fan JM Yeakley M Bibikova E Chudin E Wickham J Chen D Doucet P Rigault B Zhang R Shen C McBride HR Li XD Fu A Oliphant DL Barker MS Chee, Genome Res 2004 14 5 878 885 10.1101/gr.2167504 15123585
14. Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens. HR Li J Wang-Rodriguez TM Nair JM Yeakley YS Kwon M Bibikova C Zheng L Zhou K Zhang T Downs XD Fu JB Fan, Cancer Res 2006 66 8 4079 4088 10.1158/0008-5472.CAN-05-4264 16618727
15. Quantitative expression profiling of highly degraded RNA from formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide microarrays. M Ravo M Mutarelli L Ferraro OM Grober O Paris R Tarallo A Vigilante D Cimino M De Bortoli E Nola L Cicatiello A Weisz, Lab Invest 2008 88 4 430 440 10.1038/labinvest.2008.11 18305565
16. Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. C April B Klotzle T Royce E Wickham-Garcia T Boyaniwsky J Izzo D Cox W Jones R Rubio K Holton U Matulonis J Quackenbush JB Fan, PLoS One 2009 4 12 8162 10.1371/journal.pone.0008162 19997620
17. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. J Chien JB Fan DA Bell C April B Klotzle T Ota WL Lingle J Gonzalez Bosquet V Shridhar LC Hartmann, Gynecol Oncol 2009 114 1 3 11 10.1016/j.ygyno.2009.04.002 19410283
18. Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay. N Waddell S Cocciardi J Johnson S Healey A Marsh J Riley L da Silva AC Vargas L Reid PT Simpson SR Lakhani G Chenevix-Trench, J Pathol 2010 221 4 452 461 20593485
19. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik MD Pegram EA Perez MF Press A Rhodes C Sturgeon SE Taube R Tubbs GH Vance M van de Vijver TM Wheeler DF Hayes, J Clin Oncol 2007 25 1 118 145 10.1200/JCO.2006.09.2775 17159189 (Pubitemid 350003059)
20. Herceptin (trastuzumab). Package insert. San Francisco, CA: Genentech Inc 2008 http://www.gene.com/gene/products/information/oncology/herceptin/
21. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. T Nakagawa TM Kollmeyer BW Morlan SK Anderson EJ Bergstralh BJ Davis YW Asmann GG Klee KV Ballman RB Jenkins, PLoS ONE 2008 3 5 2318 10.1371/journal.pone.0002318 18846227
22. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. R Edgar M Domrachev AE Lash, Nucleic Acids Res 2002 30 1 207 210 10.1093/nar/30.1.207 11752295
23. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. L Shi LH Reid WD Jones R Shippy JA Warrington SC Baker PJ Collins F de Longueville ES Kawasaki KY Lee Y Luo YA Sun JC Willey RA Setterquist GM Fischer W Tong YP Dragan DJ Dix FW Frueh FM Goodsaid D Herman RV Jensen CD Johnson EK Lobenhofer RK Puri U Schrf J Thierry-Mieg C Wang M Wilson PK Wolber L Zhang S Amur W Bao CC Barbacioru AB Lucas V Bertholet C Boysen B Bromley D Brown A Brunner R Canales XM Cao TA Cebula JJ Chen J Cheng TM Chu E Chudin J Corson JC Corton LJ Croner C Davies TS Davison G Delenstarr X Deng D Dorris AC Eklund XH Fan H Fang S Fulmer-Smentek JC Fuscoe K Gallagher W Ge L Guo X Guo J Hager PK Haje J Han T Han HC Harbottle SC Harris E Hatchwell CA Hauser S Hester H Hong P Hurban SA Jackson H Ji CR Knight WP Kuo JE LeClerc S Levy QZ Li C Liu Y Liu MJ Lombardi Y Ma SR Magnuson B Maqsodi T McDaniel N Mei O Myklebost B Ning N Novoradovskaya MS Orr TW Osborn A Papallo TA Patterson RG Perkins EH Peters R Peterson KL Philips PS Pine L Pusztai F Qian H Ren M Rosen BA Rosenzweig RR Samaha M Schena GP Schroth S Shchegrova DD Smith F Staedtler Z Su H Sun Z Szallasi Z Tezak D Thierry-Mieg KL Thompson I Tikhonova Y Turpaz B Vallanat C Van SJ Walker SJ Wang Y Wang R Wolfinger A Wong J Wu C Xiao Q Xie J Xu W Yang L Zhang S Zhong Y Zong W Slikker Jr, Nat Biotechnol 2006 24 9 1151 1161 10.1038/nbt1239 16964229
24. Faster cyclic loess: normalizing RNA arrays via linear models. KV Ballman DE Grill AL Oberg TM Therneau, Bioinformatics 2004 20 16 2778 2786 10.1093/bioinformatics/bth327 15166021
25. Statistical methods for identifying differentially expressed genes in replicated cdna microarray experiments. S Dudoit Y Yang M Callow T Speed, Statistica Sinica 2002 12 1 111 139
26. A language and environment for statistical computing. R Development Core Team. R, R Foundation for Statistical Computing, Vienna, Austria 2010 http://www.R-project.org ISBN 3-900051-07-0
27. A note on two problems in connexion with graphs. EW Dijkstra, Numerische Mathematik 1959 1 269 271 10.1007/BF01386390
28. TAILORx: Testing Personalized Treatment for Breast Cancer. NCI/NIH posting 2006 http://www.cancer.gov/clinicaltrials/digestpage/TAILORx
29. EORTC Trial 1004 1 (BIG 3-04)-MINDACT. EORTC European Organization for Research and Treatment of Cancer 2009 http://www.eortc.be/services/unit/mindact/ MINDACT-websiteii.asp
30. Gene-expression signatures in breast cancer. C Sotiriou L Pusztai, N Engl J Med 2009 360 8 790 800 10.1056/NEJMra0801289 19228622
31. Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. S Paik CY Kim YK Song WS Kim, Nat Clin Pract Oncol 2005 2 5 246 254 10.1038/ncponc0171 16264960
32. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. AM Hosey JJ Gorski MM Murray JE Quinn WY Chung GE Stewart CR James SM Farragher JM Mulligan AN Scott PA Dervan PG Johnston FJ Couch PA Daly E Kay A McCann PB Mullan DP Harkin, J Natl Cancer Inst 2007 99 22 1683 1694 10.1093/jnci/djm207 18000219
33. Generation of a non-small cell lung cancer transcriptome microarray. A Tanney GR Oliver V Farztdinov RD Kennedy JM Mulligan CE Fulton SM Farragher JK Field PG Johnston DP Harkin V Proutski KA Mulligan, BMC Med Genomics 2008 1 20 10.1186/1755-8794-1-20 18513400
34. Expression signatures that correlated with Gleason score and relapse in prostate cancer. M Bibikova E Chudin A Arsanjani L Zhou EW Garcia J Modder M Kostelec D Barker T Downs JB Fan J Wang-Rodriguez, Genomics 2007 89 6 666 672 10.1016/j.ygeno.2007.02.005 17459658
35. Illumina - Annotation Files. 2009 http://www.switchtoi.com/ annotationfiles.ilmn
36. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. MJ Kim JY Ro SH Ahn HH Kim SB Kim G Gong, Hum Pathol 2006 37 9 1217 1226 10.1016/j.humpath.2006.04.015 16938528
37. The genomic profile of HER2-amplified breast cancers: the influence of ER status. C Marchio R Natrajan KK Shiu MB Lambros SM Rodriguez-Pinilla DS Tan CJ Lord D Hungermann K Fenwick N Tamber A Mackay J Palacios A Sapino H Buerger A Ashworth JS Reis-Filho, J Pathol 2008 216 4 399 407 10.1002/path.2423 18810758
38. Microarray platform consistency is revealed by biologically functional analysis of gene expression profiles. Z Li Z Su Z Wen L Shi T Chen, BMC Bioinformatics 2009 10 Suppl 11 12 10.1186/1471-2105-10-S11-S12 19811677
39. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. G Konecny G Pauletti M Pegram M Untch S Dandekar Z Aguilar C Wilson HM Rong I Bauerfeind M Felber HJ Wang M Beryt R Seshadri H Hepp DJ Slamon, J Natl Cancer Inst 2003 95 2 142 153 10.1093/jnci/95.2.142 12529347 (Pubitemid 36193263)
40. Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. Y Kun LC How TP Hoon VB Bajic TS Lam A Aggarwal HG Sze WS Bok WC Yin P Tan, Hum Mol Genet 2003 12 24 3245 3258 10.1093/hmg/ddg347 14570715
41. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. P Lal LK Tan B Chen, Am J Clin Pathol 2005 123 4 541 546 10.1309/YMJ3A83TB39MRUT9 15743737
42. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. LD Read D Keith Jr DJ Slamon BS Katzenellenbogen, Cancer Res 1990 50 13 3947 3951 1972345
43. Gene expression phenotypic models that predict the activity of oncogenic pathways. E Huang S Ishida J Pittman H Dressman A Bild M Kloos M D'Amico RG Pestell M West JR Nevins, Nat Genet 2003 34 2 226 230 10.1038/ng1167 12754511
44. Gene expression phenotypes of oncogenic signaling pathways. ES Huang EP Black H Dressman M West JR Nevins, Cell Cycle 2003 2 5 415 417 12963829
45. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. AH Bild G Yao JT Chang Q Wang A Potti D Chasse MB Joshi D Harpole JM Lancaster A Berchuck JA Olson Jr JR Marks HK Dressman M West JR Nevins, Nature 2006 439 7074 353 357 10.1038/nature04296 16273092
46. Multiclass cancer diagnosis using tumor gene expression signatures. S Ramaswamy P Tamayo R Rifkin S Mukherjee CH Yeang M Angelo C Ladd M Reich E Latulippe JP Mesirov T Poggio W Gerald M Loda ES Lander TR Golub, Proc Natl Acad Sci USA 2001 98 26 15149 15154 10.1073/pnas.211566398 11742071
47. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. CR Acharya DS Hsu CK Anders A Anguiano KH Salter KS Walters RC Redman SA Tuchman CA Moylan S Mukherjee WT Barry HK Dressman GS Ginsburg KP Marcom KS Garman GH Lyman JR Nevins A Potti, Jama 2008 299 13 1574 1587 10.1001/jama.299.13.1574 18387932
48. Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. JR Nevins ES Huang H Dressman J Pittman AT Huang M West, Hum Mol Genet 2003 12 Spec No 2 153 157 10.1093/hmg/ddg287 12928487